Leading manufacturers of vaccines and antiviral drugs are working hard to develop new and novel methods of preparing seasonal influenza vaccines, as well as pandemic vaccine candidates [ 4]. Until recently, most efforts have been focused on improving currently licensed egg- based vaccines. Manufacturers have been racing to increase production capacities and automate portions of largely manual steps in egg-based vaccine technology to meet the demands of the next seasonal campaign and to generate prototypes of pandemic vaccines for clinical trials. At least 30 clinical trials of avian pandemic prototype vaccines are in progress, and manufacturers are working with international agencies, such as the World Health Organization, European Medicines Agency, and the National Institutes of Health, on the development, licensing, and production of pandemic vaccines on a global scale. Currently, about 25 of these projects are based on classical egg-based technology, and six are based on cell-culture systems (Chiron has one cell-culture vaccine in the final stages of development and approval by regulatory agencies).